Market Overview

Eureka Therapeutics to Present Proof-of-Concept Preliminary Data from Ongoing China Clinical Study of ET140202 at CAR-TCR 2018 Summit

Share:

Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company
with the goal of curing cancer by developing novel T-cell therapies that
harness the evolutionary power of the immune system, today announced
that new proof-of-concept preliminary data from its ongoing China
clinical study evaluating ET140202 for the treatment of AFP-positive
hepatocellular carcinoma (AFP+ HCC) will be presented as a late-breaking
oral presentation at the 4th Annual CAR-TCR Summit in Boston,
Massachusetts, September 4-7, 2018.

The presentation details are listed below and are accessible on the 4th
Annual CAR-TCR Summit website:

Presentation Title: Case Report of Regression of Metastatic Liver
Cancer After ET140202 T-Cell Therapy
Session Title: Late
Breaking Abstracts
Date & Time: Wednesday, September 5,
2018 from 9:15 a.m. – 9:35 a.m. ET
Location: Seaport
Hotel & World Trade Center

Presentation Title: Improvement of Safety in T-cell
Immunotherapies for the Treatment of Cancer
Session Title:
Overcoming CAR-T Toxicity in Solid Tumors (Agenda 1)
Date & Time:
Friday, September 7, 2018 from 1:00 p.m. – 1:30 p.m. ET
Location:
Seaport Hotel & World Trade Center

About Eureka Therapeutics, Inc.

Eureka Therapeutics, Inc. is a privately held clinical stage
biopharmaceutical company focused on developing novel T-cell therapies
that harness the evolutionary power of the immune system. Its core
technology platforms center around its proprietary ARTEMIS™ T-cell
receptor platform and E-ALPHA® antibody discovery platform for the
discovery and development of potentially safer and more effective T-cell
therapies for the treatment of multiple solid and hematologic tumors.

Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay
Area. For more information on Eureka, please visit www.eurekatherapeutics.com.

View Comments and Join the Discussion!